Lexicon Pharma (NASDAQ:LXRX) +8.5% premarket after its LX1033 drug candidate for irritable bowel syndrome receives fast track status from the FDA.
Lexicon Pharma (NASDAQ:LXRX) +8.5% premarket after its LX1033 drug candidate for irritable bowel...
Recommended For You
More Trending News
About LXRX Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| LXRX | - | - |
| Lexicon Pharmaceuticals, Inc. | ||